2012, Número 1
<< Anterior Siguiente >>
Ann Hepatol 2012; 11 (1)
Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis
Mederacke I, Helfritz F, Puls F, Ringe KI , Klempnauer J, Manns MP, Strassburg CP
Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 143-144
Archivo PDF: 147.57 Kb.
FRAGMENTO
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
Strassburg CP. Autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2010; 24: 667-82.
Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25: 927-34.
Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-206.
Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-90.
Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in earlyand late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202.
Plessier A, Valla DC. Budd-Chiari syndrome. Semin Liver Dis 2008; 28: 259-69.